CA
NZ
UK
US
AU
IND
Last update at 2024-11-11T14:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX
Tue 19 Apr 22, 11:00 AM| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Income before tax | -26.92000M | -14.23300M | -4.76100M | -3.61500M | -2.40025M |
| Minority interest | - | - | - | - | - |
| Net income | -25.74600M | -14.23300M | -4.76100M | -3.61500M | -2.43696M |
| Selling general administrative | 25.04M | 16.26M | 5.46M | 5.05M | 3.22M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 6.28M | 3.96M | 1.38M | 1.40M | 0.83M |
| Reconciled depreciation | 1.42M | 0.74M | 0.42M | 0.14M | - |
| Ebit | -16.79800M | -11.38200M | -4.24700M | -3.73700M | - |
| Ebitda | -19.04100M | -12.13400M | -3.73900M | -3.40700M | - |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -19.60400M | -12.81700M | -4.34300M | -3.73700M | -2.28294M |
| Other operating expenses | - | - | - | - | - |
| Interest expense | 6.46M | 1.36M | 0.60M | 0.07M | 0.00000M |
| Tax provision | -1.17400M | 0.00000M | 0.00000M | 0.00000M | 0.04M |
| Interest income | 7.11M | 1.38M | 0.42M | 0.07M | 0.17M |
| Net interest income | -6.32700M | -1.38700M | -0.61300M | -0.13400M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.17400M | - | - | - | - |
| Total revenue | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M |
| Total operating expenses | 46.85M | 26.25M | 11.77M | 10.31M | - |
| Cost of revenue | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M |
| Total other income expense net | -1.48300M | -0.15300M | 0.15M | 0.26M | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -25.74600M | -14.23300M | -4.76100M | -3.61500M | - |
| Net income applicable to common shares | -25.74600M | -14.23300M | -4.76100M | -3.61500M | -2.43696M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Total assets | 41.21M | 58.27M | 21.03M | 10.96M | 5.81M |
| Intangible assets | 13.30M | 15.48M | 6.54M | 4.95M | 3.86M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | - |
| Total liab | 81.54M | 76.11M | 18.98M | 7.89M | 5.83M |
| Total stockholder equity | -40.33700M | -17.84800M | 2.05M | 3.07M | -0.02200M |
| Deferred long term liab | - | 1.87M | 2.81M | 2.75M | 1.88M |
| Other current liab | - | 4.29M | 2.75M | 0.72M | 0.60M |
| Common stock | - | 26.36M | 24.62M | 15.02M | 8.83M |
| Capital stock | 31.70M | 26.36M | 24.62M | 15.02M | 8.83M |
| Retained earnings | -82.26400M | -54.45600M | -28.71000M | -14.47700M | -9.71600M |
| Other liab | - | 0.13M | 0.87M | 0.42M | 0.35M |
| Good will | - | - | - | - | - |
| Other assets | - | 1.87M | 2.81M | 2.75M | 1.88M |
| Cash | 7.50M | 22.50M | 2.04M | 2.84M | 0.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 20.27M | 15.34M | 15.33M | 4.28M | 4.48M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 56.26M | 37.77M | 4.42M | 0.13M | 0.67M |
| Short term debt | - | 0.74M | 0.00000M | 0.00000M | 0.00000M |
| Short long term debt | 4.60M | 0.74M | 4.85M | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | 5.84M | 3.75M | 0.91M | 0.27M |
| Property plant equipment | - | 2.25M | 2.14M | 0.60M | 0.30M |
| Total current assets | 25.24M | 40.53M | 12.35M | 5.41M | 1.65M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -31.46100M | -1.67600M | 0.87M | -2.00200M |
| Short term investments | - | - | - | - | - |
| Net receivables | 6.42M | 5.43M | 1.80M | 1.22M | 0.61M |
| Long term debt | 59.16M | 59.53M | 1.60M | 2.97M | 1.00M |
| Inventory | 10.25M | 9.98M | 7.67M | 0.88M | 0.56M |
| Accounts payable | 3.99M | 3.74M | 7.32M | 3.38M | 3.84M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 15.96M | 17.74M | 8.68M | 5.55M | 4.16M |
| Capital lease obligations | 1.40M | 1.17M | 1.21M | 0.29M | - |
| Long term debt total | - | 60.65M | 2.77M | 3.20M | 1.00M |
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 |
| Investments | -6.89100M | -3.46500M | -1.40500M | -0.92300M | - |
| Change to liabilities | -4.01700M | 6.42M | -0.67500M | 0.96M | - |
| Total cashflows from investing activities | -6.89100M | -3.46500M | -1.40500M | -0.92300M | 0.06M |
| Net borrowings | 19.67M | 3.52M | 2.75M | 0.95M | - |
| Total cash from financing activities | 54.99M | 15.10M | 9.21M | 3.55M | 1.28M |
| Change to operating activities | -0.02700M | -0.26500M | -0.22600M | -0.19600M | - |
| Net income | -25.74600M | -14.23300M | -4.76100M | -3.61500M | -2.43696M |
| Change in cash | 20.46M | -0.79300M | 2.50M | 0.32M | 0.00819M |
| Begin period cash flow | 2.04M | 2.84M | 0.34M | 0.01M | - |
| End period cash flow | 22.50M | 2.04M | 2.84M | 0.34M | 0.01M |
| Total cash from operating activities | -28.50300M | -12.31500M | -5.29800M | -2.30700M | -1.33345M |
| Issuance of capital stock | 0.00000M | 11.50M | 7.24M | 3.11M | - |
| Depreciation | 1.13M | 0.48M | 0.31M | 0.10M | 0.04M |
| Other cashflows from investing activities | - | - | 0.00000M | 0.02M | 0.39M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -3.81300M | -6.98200M | -0.52500M | -0.46800M | - |
| Change to account receivables | -3.62700M | -0.58300M | -0.71000M | 0.35M | - |
| Sale purchase of stock | 0.39M | 13.22M | 7.24M | 3.11M | - |
| Other cashflows from financing activities | 34.93M | 1.20M | -0.24200M | 0.02M | -0.07124M |
| Change to netincome | 7.31M | 2.59M | 1.18M | 0.51M | - |
| Capital expenditures | 0.36M | 0.90M | 0.06M | 0.03M | 0.32M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -11.48400M | -1.41200M | -2.13600M | 0.65M | 0.79M |
| Stock based compensation | 0.94M | 1.00M | 0.47M | 0.33M | - |
| Other non cash items | 3.54M | 1.06M | 0.50M | 0.09M | - |
| Free cash flow | -35.39400M | -15.78000M | -6.70300M | -3.25200M | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VPH Valeo Pharma Inc |
- -% | 0.04 | - | - | 0.08 | 71.69 | 1.26 | -4.4191 |
| BHC Bausch Health Companies Inc |
-0.14 2.13% | 6.42 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.05 4.13% | 1.16 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
-0.01 1.64% | 0.60 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.01 0.54% | 2.79 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.
16667 Hymus Boulevard, Kirkland, QC, Canada, H9H 4R9
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven Saviuk CA | Vice Chairman & CEO | 1959 |
| Mr. Luc Mainville M.B.A, M.B.A. | Sr. VP & CFO | 1964 |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corp. Sec. | NA |
| Mr. Frederic Dumais | Director of Communications & Investor Relations | NA |
| Mr. Kyle Steiger | Sr. VP & Chief Commercial Officer | NA |
| Mr. Jean Francois Fournier | Head of Ophthalmology Bus. Unit | NA |
| Mr. Kyle Steiger | Senior VP & Chief Commercial Officer | NA |
| Mr. Al Moghaddam B. Com. Cma | Chief Executive Officer | 1967 |
| Mr. Pascal Tougas | Chief Financial Officer | NA |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...